vigabatrin has been researched along with Alpers Diffuse Degeneration of Cerebral Gray Matter with Hepatic Cirrhosis in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "A patient with hepatic cirrhosis due to Alpers disease is described who had a significantly raised plasma alanine aminotransferase (ALT) activity of 247 U/L which returned to normal (18 U/L) shortly after commencing treatment with the anticonvulsant drug, vigabatrin." | 1.30 | Suppression of elevated alanine aminotransferase activity in liver disease by vigabatrin. ( Coakley, J; Sekaninova, S; Williams, A, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Williams, A | 1 |
| Sekaninova, S | 1 |
| Coakley, J | 1 |
1 other study available for vigabatrin and Alpers Diffuse Degeneration of Cerebral Gray Matter with Hepatic Cirrhosis
| Article | Year |
|---|---|
Suppression of elevated alanine aminotransferase activity in liver disease by vigabatrin.
Topics: Alanine Transaminase; Anticonvulsants; Diffuse Cerebral Sclerosis of Schilder; Enzyme Inhibitors; Fa | 1998 |